Login
$MGTX
$9.40 +$0.22 (2.4%) Close

Company Executives

$MGTX Management Team

Dr. Alexandria Forbes

President

Chief Executive Officer

Director

Age 60
Compensation $6.876M USD
Sex Female

Mr. Richard Giroux

Chief Financial Officer

Chief Operating Officer

Age 52
Compensation $6.694M USD
Sex Male

Mr. Robert Wollin

General Counsel

Secretary

Age 49
Compensation -
Sex Male

Dr. Stuart Naylor

Chief Development Officer

Age 62
Compensation $2.025M USD
Sex Male

Mr. Robert Zeldin

Chief Medical Officer

Age 62
Compensation $4.047M USD
Sex Male

Dr. Keith Harris

Independent Chairman of the Board

Age 72
Compensation $529.1K USD
Sex Male
Directors
7
serving now
Independent
5 of 7
stated in the proxy
Average tenure
9.1 years
from year joined
CEO also chairs the board
No
Keith R. Harris, Ph.D.
Director Age On board Independent Committees Other public boards 2025 pay Source
Ellen Hukkelhoven, Ph.D.
39 2017
9 years
Not independent None stated Freenome Holdings, Inc., Partner Therapeutics, Inc. $296,550
Nicole Seligman
69 2019
7 years
Independent None stated Intuitive Machines, Inc., OpenAI, Praetorian Acquisition Corp. $406,050
Debra Yu, M.D.
61 2022
4 years
Independent None stated JW (Cayman) Therapeutics Co. Ltd. $389,050
Thomas E. Shenk, Ph.D.
79 2015
11 years
Independent None stated None stated $398,550
Alexandria Forbes, Ph.D.
61 2015
11 years
Not independent None stated None stated Paid as CEO
Keith R. Harris, Ph.D.
73 2015
11 years
Independent None stated Global Connectivity PLC $674,250
Lord Mendoza
66 2015
11 years
Independent None stated None stated $396,550

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Directors and executive officers
directors and executive officers
Amount not stated

Indemnification agreements with each director and executive officer

Perceptive Credit Holdings
affiliate of Perceptive, a beneficial owner of more than 5% of our ordinary shares
$75.0 million
2022

Senior secured financing (Notes Purchase Agreement) with initial $75.0 million notes issuance

With Company as borrower Open in proxy
Perceptive Master Fund
$18,193,000

Company repurchased 2,300,000 ordinary shares under a share purchase agreement

Sanofi
beneficial holder of more than 5% of our ordinary shares at that time
Amount not stated
2024

Purchased 7,500,000 ordinary shares in August 2024 public offering

Perceptive Advisor
beneficial holder of more than 5% of our ordinary shares at that time
Amount not stated
2024

Purchased 1,250,000 ordinary shares in August 2024 public offering

Prosight Management, LP
beneficial holder of more than 5% of our ordinary shares at that time
Amount not stated
2024

Purchased 375,000 ordinary shares in August 2024 public offering

Rubric Capital
beneficial holder of more than 5% of our ordinary shares
Amount not stated
2026

Purchased 1,600,000 ordinary shares in April 2026 public offering

Perceptive Advisor
beneficial holder of more than 5% of our ordinary shares
Amount not stated
2026

Purchased 555,555 ordinary shares in April 2026 public offering

Adage
beneficial holder of more than 5% of our ordinary shares
Amount not stated
2026

Purchased 400,000 ordinary shares in April 2026 public offering

Hologen Limited
$200 million
2025

Strategic collaboration with upfront cash payment to the Company and related framework agreements

Dr. Forbes and Mr. Giroux
received a nominal equity interest in Hologen and are members of Hologen's Scientific Advisory Board and Advisory Board, respectively
Amount not stated
2025

Nominal equity interest in Hologen held by Dr. Forbes and Mr. Giroux, who serve on Hologen advisory boards

With Hologen Limited Open in proxy
Johnson & Johnson Innovation – JJDC, Inc.
owner of Seller and owns more than 5% of our outstanding shares
$25,000,000
2026

Asset Purchase Agreement for RPGR gene therapy product and related assets with upfront cash purchase price to Seller

With Janssen Pharmaceuticals, Inc. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support